Professor of Molecular Biology, Director at the Max Planck Institute for Experimental Medicine

• 1987 PhD, University of California, San Diego


• 1987-1991 Postdoc, The Salk Institute, la Jolla, California


• 1991 Junior Group Leader, ZMBH, University of Heidelberg


• 1998 Professor of Molecular Biology (C4), ZMBH, University of Heidelberg


• - 2000 Director, Department of Neurogenetics, Max Planck Institute for Experimental Medicine Göttingen and Professor of Biology, University of Heidelberg

Major Research Interests

We are interested in the mechanisms of neuron-glia interactions in the higher nervous system, and in the genes that are required for normal glial cell function. Here, transgenic and mutant mice have become important to study developmental processes as well as genetic diseases. For example, oligodendrocytes are glial cells highly specialized for enwrapping CNS axons with multiple layers of membranes, known to provide electrical insulation for rapid impulse propagation. We found that oligodendrocytes are also essential for maintaining the long-term integrity of myelinated axons, independent of the myelin function itself. The mechanisms by which oligodendrocytes support long-term axonal survival are still under investigation. The importance of glial cells as the "first line of neuroprotection", however, is illustrated by several myelin-associated diseases in which axonal neurodegeneration contribute to progressive disability. These range in humans from peripheral neuropathies (CMT1) to spastic paraplegia (SPG2), and presumably multiple sclerosis (MS) and certain forms of psychiatric disorders. We are developing transgenic animal models for some of these diseases, in order to dissect the underlying disease mechanisms and, in the case of CMT1A, have used these models to design novel therapeutic strategies.

The glial "decision" to myelinate an axonal segment is partly controlled by the axon itself, but the signaling mechanism is not understood. We have found that axonal neuregulin-1 (NRG1) is the major determinant of myelination in the peripheral nervous system. We are now investigating NRG1 dysregulation also in CNS myelination, using quantifiable behavioural functions in mice. By combining genetics with enviromental risk factors for schizophrenia (in collaboration with H. Ehrenreich) we will explore the hypothesis that NRG1, a known human schizophrenia susceptibility gene, points to an important role of myelinating glia in some psychiatric disorders.

Future Projects and Goals

Mechanisms of neuron-glia signalling; function of myelin proteins and lipids; transcriptional profiling of single cells in vivo; novel mouse models of neuropsychiatric disorders.


Homepage Department/Research Group

http://www.em.mpg.de/index.php?id=34&no_cache=1



Selected Recent Publications

• Stassart RM, Fledrich R, Velanac V, Brinkmann BG, Schwab MH, Meijer D, Sereda MW, Nave K-A (2012). A role for Schwann cell derived neuregulin-1 in remyelination. Nat. Neurosci (in press)


• Saher G, Rudolphi F, Corthals K, Ruhwedel T, Schmidt KF, Löwel S, Dibaj P, Barrette B, Möbius W, Nave K-A (2012). Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat Med. 18, 1130-1135


• Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave K-A (2012). Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517-521


• Goebbels S, Oltrogge JH, Wolfer S, Wieser GL, Nientiedt T, Pieper A. Ruhwedel T, Groszer M, Sereda MW, Nave K-A (2012). Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy. EMBO Mol Med. 4, 486-499


• Dhaunchak AS, Colman DR, Nave K-A (2011). Misalignment of PLP/DM20 transmembrane domains determines protein misfolding in Pelizaeus-Merzbacher disease. J Neurosci. 31,14961-14971


• Nave K-A (2010). Myelination and support of axonal integrity by glia. Nature 468, 244-252